Brief: First Wave BioPharma Presents Research On Improved Adrulipase Drug Delivery Formulation
10/10/2022 12:41
Oct 10 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA PRESENTS RESEARCH DEMONSTRATING
BENEFITS OF
IMPROVED ADRULIPASE DRUG DELIVERY FORMULATION AT AAPS 2022
PHARMSCI 360
Source text for Eikon: ID:nGNX9jmkJ0
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement